Practice
For the full versions of these articles see bmj.com
[All based on registry database evidence and the experience and opinion of the GDG]
Use the risk scoring system to predict six month mortality and hence the patient's risk (table) .
Use this risk assessment to guide clinical management, balancing the benefit of treatment against any related adverse events. [Based on the experience and opinion of the GDG] antiplatelet treatment Offer a single loading dose of 300 mg aspirin as soon as possible and continue indefinitely unless contraindicated by bleeding risk or aspirin hypersensitivity.
[Based on a high quality systematic review and cost effectiveness evidence]
Offer a loading dose of 300 mg clopidogrel in addition to aspirin to patients with a predicted six month mortality of more than 1.5%, or to patients who may undergo percutaneous coronary intervention within 24 hours of admission to hospital, unless contraindications (for example, excessive risk of bleeding) exist. [Based on moderate to high quality evidence from randomised controlled trials (RCTs) 
and cost effectiveness evidence]
Consider adding an intravenous glycoprotein IIa/IIIb inhibitor (eptifibatide or tirofiban) as part of early management for patients at intermediate or higher risk (predicted six month mortality >3.0%) who are scheduled to undergo coronary angiography (and follow-on percutaneous coronary intervention if indicated) within 96 hours of hospital admission. (This is an off-label use of eptifibatide and tirofiban, which do not have marketing authorisation for use with clopidogrel in the United Kingdom.) [ 
Why read this summary?
Acute coronary syndromes are a common cause of morbidity and mortality, and they place a major burden on healthcare providers in both industrialised and developing countries. A range of drug treatments and invasive management strategies is available, but the potential to reduce ischaemic risk must be balanced against the increased risk of bleeding complications. This article summarises recommendations made in the National Institute for Health and Clinical Excellence (NICE) guideline for the management of unstable angina and non-ST elevation myocardial infarction, including risk assessment, drug treatment, invasive management, cardiac rehabilitation, and planning of discharge.
1 Patients with acute coronary syndrome who do not have persistent ST segment elevation on their electrocardiogram (ECG) at presentation are classified as having non-ST elevation myocardial infarction if the serum troponin concentration is raised and as having unstable angina if it is n ormal. recommendations NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the experience and opinion of the Guideline Development Group (GDG) on what constitutes good practice. FurTher inFormaTion on The guidanCe If untreated, the prognosis for patients with unstable angina or non-ST elevation myocardial infarction is poor, and after six to 12 months of follow-up mortality is often as high or higher than for patients with ST elevation infarction. Appropriate triage and timely use of acute interventions, whether invasive or drug based, can greatly improve outcomes, but these interventions are themselves associated with increased bleeding. The main aim of this guideline is to provide advice about balancing these risks and to help clinicians determine the best treatment for patients with differing severities of unstable angina or non-ST elevation myocardial infarction.
This guidance updates previously published health technology appraisals of clopidogrel and glycoprotein IIb/IIIa inhibitors. 5 6 meThodology The guideline was developed according to NICE guideline methodology (www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/ clinicalguidelinedevelopmentmethods/theguidelinesmanual2007/the_guidelines_ manual_2007.jsp). This involved systematic searching, critically appraising, and summarising the clinical and cost effectiveness evidence. New cost effectiveness analysis was also undertaken, exploring the use of glycoprotein IIb/IIIa inhibitors in combination with clopidogrel and bivalirudin as a possible alternative to heparin plus a glycoprotein IIb/IIIa inhibitor. A multi-disciplinary GDG discussed the evidence and formulated clinical recommendations. The guideline went through an external consultation with stakeholders. The GDG assessed the comments, reanalysed the data where necessary, and modified the guideline.
NICE has produced four different versions of the guideline: a full version; a quick reference guide; a version known as the "NICE guideline" that summarises the recommendations; and a version for patients and the public. All these versions are available from the NICE website (www. nice.org.uk.CG94). Future updates of the guideline will be published according to the NICE guideline development programme.
FuTure researCh
•The role of myocardial ischaemia testing in people after acute coronary syndrome and the comparative efficacy and cost effectiveness of different non-invasive tests (such as stress ECG, magnetic resonance imaging, echocardiography, and radionuclide scanning) •The use of combined risk scoring systems (in addition to clinical assessment) of ischaemic outcomes and bleeding complications, compared with clinical assessment alone, to determine net clinical benefit •Comparison of data on clinical outcomes (adverse cardiovascular events and bleeding complications) from cardiac registries with data collected in randomised controlled trials 
Overcoming barriers
Implementing this guideline will require increased use of risk scoring systems to improve risk stratification and identification of people with unstable angina and non-ST elevation myocardial infarction who would probably benefit from recommended drugs and invasive treatments. Using fondaparinux as the standard antithrombin drug will require a change in current practice, but this drug is easy to administer as a single, non-weight adjusted daily dose, and it does not require titration unless renal function is particularly impaired (serum creatinine >265 µmol/l). The recommendation for coronary angiography (with follow-on percutaneous coronary intervention if indicated) within 96 hours of first hospital admission for those with a predicted six month mortality greater than 3% will require systems to be developed for early access to interventional cardiology services. Clinical judgment is required to balance the potential for reducing ischaemic risk with the increased risk of bleeding complications, although emerging clinical scoring systems for bleeding risk may prove helpful.
Members of the Guideline Development Group: Sotiris Antoniou, Lina Bakhshi, Jenny Cadman, John Camm, Emily Crowe, Mark de Belder, Jose Diaz, David H Geldard, Huon Gray, Robert Henderson, Marjan Jahangiri, Taryn Krause, Kate Lovibond, Gavin Maxwell, Francis Morris, Alun Roebuck, Nicola Sloan, Claire Turner, S Richard Underwood, and Mark Whitbread. Contributors: EC drafted the article. All authors revised it critically for important intellectual content and approved the final version to be published. HG is guarantor of this article and accept full responsibility for the work. Funding: The National Clinical Guideline Centre was commissioned and funded by the National Institute for Health and Clinical Excellence to write this summary. Competing interests: All authors were members of the Guideline Development Group for the NICE guideline (EC the systematic reviewer, KL the health economist, RH a GDG member, TK the project manager, HG the clinical lead, and JC the chair). All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that (1) All authors had no financial support for the submitted work from anyone other than their employer; (2) In the previous three years RH has received honorariums or travel grants (or both) from Cordis UK, Abbott Vascular, Cordis UK, Boston Scientific, Lilly, Pfizer, Lilly UK, and Daichii Sankyo; HG has received honorariums from Lilly and Medicines Company; JC has chaired a session at the AHA meeting supported by Sanofi-Aventis on clopidogrel and received a travel grant from Sanofi-Aventis; KL worked for Medaxial before April 2008; the other authors declare no relationships; (3) All authors have no spouses, partners, or children with financial relationships that may be relevant to the submitted work; and (4) All authors have no non-financial interests that may be relevant to the submitted work. provenance and peer review: Commissioned; not externally peer reviewed. Pandemic flu is nothing new, and in the three years from 1889 the world was, as now, in its grip. The year 1891 found a little known Dr Conan Doyle struggling to build an ophthalmic practice in two rented rooms, one to be a consulting room and the other a waiting room, close to Harley Street. He later wrote that both proved to be waiting rooms, so that it was from there that he was able to submit for publication his first successful Sherlock Holmes stories, collected in The Adventures of Sherlock Holmes.
Then in August of that year Conan Doyle contracted influenza. He dramatised the event-justifiably perhaps, as 18 months earlier his sister Annette had died of influenza. "For a week I was in great danger and then found myself as weak as a child and as emotional, but with a mind as clear as crystal. It was then… I saw how foolish I was to waste my literary earnings in keeping up an oculist's room in Wimpole Street, and I determined… to trust forever to my power of writing… I should at last be my own master. No longer should I have to conform to professional dress or try to please anyone else."
The same month Conan Doyle terminated his medical practice and sold his eye instruments (for £6 and 10 shillings). The Adventures of Sherlock Holmes was dedicated to his Edinburgh teacher Dr Joseph Bell. Bell returned the compliment in a review in The Bookman: "Conan Doyle's education as a student of medicine taught him how to observe, and his practice, both as a general practitioner and a specialist, has been a splendid training for a man such as he is, gifted with eyes, memory and imagination… Such are the mysteries of his trade as a diagnostician… if in addition the doctor is a born storyteller."
It is only fair to add that Conan Doyle had already struggled for a decade to make a literary living and had not found writing an easy escape route from medicine. Practice a CardiologisT's perspeCTive Cardiomyopathy is disease of the heart muscle that results in abnormal cardiac function. Patients can experience a range of symptoms according to the degree of cardiac dysfunction: from being completely asymptomatic to experiencing major health problems such as heart failure, increased risk of thromboembolism, and sudden cardiac death, commonly the result of arrhythmias.
There are various forms and causes of cardiomyopathy. The commonest form is dilated cardiomyopathy, in which the left ventricle or both ventricles are dilated with impaired contraction. Causes of this condition include ischaemia, excessive alcohol intake, thyroid disorders, and valvular lesions. Management is often concerned with treating the underlying cause. Accordingly, clinicians often have to ask many questions to help differentiate what may have led to the cardiomyopathy. This may explain why our patient perceived the doctor's behaviour as probing and prying. Liana was referred to the Royal Brompton Hospital in London for a second opinion. While she was there cardiac transplantation was discussed; she was not a candidate for cardiac transplantation because of her alcoholic liver disease (although she had been abstinent for some time) and the substantial residual functional impairment from her stroke.
Other management options are largely symptomatic and are principally directed towards treatment of developing heart failure; and the prevention of thromboembolism and sudden death. If patients are identified as being at high risk of major arrhythmic events, implantable cardioverter defibrillators should be considered as they are useful in preventing sudden death. Seventy per cent of patients with dilated cardiomyopathy are dead within five years. Prognosis depends largely on the degree of heart failure and the impairment in ventricular function.
Kathy Webb-peploe as the cardiomyopathy came just when I was starting to get my life together. I was at my fittest and I was eating better. I was riding my bike and was running marathons. But the cardiomyopathy had been lying dormant for a while.
Feelings of guilt
The doctors asked me lots of intrusive questions, which didn't help my feelings much; they implied that I drank a lot. They thought I was drinking half a bottle of gin a day. Subsequently, I found I was the only person of whom they asked these questions about my alcohol intake. It went round the ward like wild fire, and the nurses suddenly labelled me an alcoholic. Obviously I felt guilty about the whole thing; I'd brought it on myself. I was probably drinking about three bottles of wine a week. I really had cut it down, as previously I This patient reflects on the background to her cardiomyopathy, possible contributory factors, and the ways in which she has come to terms with it My journey started last autumn at work. Feeling "off colour" and nauseous, I went to my local accident and emergency department. It was quite amusing because they took my temperature and it was so low they asked me, "Are you alive?" I was admitted to the Royal Sussex County Hospital and stayed there for two months, during which time I was diagnosed with cardiomyopathy.
I had been aware that my physical strength had been diminishing. Previously, I had always been the one to stride out in front; yet when walking with my mother lately I had been unable to keep up. It was unfortunate a psyChiaTrisT's perspeCTive I was asked to see Liana by her cardiology team, who had concerns that her mood was low. I introduced myself in my habitual manner, as a psychiatrist who works in the general hospital and who specialises in the interaction between physical and mental health. At first, Liana seemed unenthusiastic about speaking to me and immediately said that she didn't want to talk about death, so we didn't, though I think that for both of us death was the elephant in the hospital bay. However, that did not mean that we talked about unimportant matters. Liana spoke eloquently about the blame that she experienced, particularly from the medical profession, which made her angry; and about feeling guilty that perhaps she was indeed to blame for her condition-both for the cardiomyopathy and the subsequent stroke. She had been a moderately heavy drinker but thought she had reduced her alcohol intake to a level that was compatible with good health.
It was interesting to note her comments about how better continuity of support from professionals might have helped. She expressed her sadness at the sudden and unexpected loss of her youthful energy and hope for the future. In terms of how she coped, she began by telling us she was "laid back," suggesting to me that this attribute had helped her come to terms with her condition. Importantly she spoke about the importance of being able to relinquish control-that she now was unable to do very much and was reliant on others. However, her determination to survive longer than her original prognosis was also evident, and her strength of mind was in large part getting her through this. I was surprised by how, in her heart, she perceived her whole self as "ugly" and not just the appearance of her clawlike paralysed hand. I was struck by her dignity and beauty, and her ability to describe her experience with such clarity. Her sad tale was interspersed with moments of real (often black) humour. was drinking a bottle of wine a day. I knew I did have a problem and it had been ongoing for a number of years. I think they forget that I'm a child of the '80s, so no one was telling us how much to drink or smoke. I keep trying to justify my cardiomyopathy; it may have been the drinking-that certainly contributed to it-but there are other possible reasons, too. It could have been a viral illness. But there's more guilt when it's related to alcohol, at least for me as a woman. I feel guilty about drinking because it's limiting my life. It's brought me to the situation I'm in now. After I had my pacemaker put in I had a stroke. I have very little understanding of what happened, but the doctors wanted to go down the same path of believing it was my alcohol intake because it was convenient; it was a good way to label me again. Everybody took the doctors' word, not my word.
My ugly side
After the stroke my left hand and leg were affected. So along with my breathlessness I now had an ugly side. Ugly is a strong word. My self image is no longer my own. It's not me anymore; it's tubes and tablets. I don't look in the mirror anymore; the girl I see looks out with eyes that look ill. I don't look nice. My body has changed so much. Previously I was tall and quite athletic looking; now I'm small and I have to ask people for help with everything. coping and accessing support They told me it was my heart, but it actually made no difference to me, I'm quite a laid back person. I wasn't aware of a support group. You don't get any support until they discharge you; which is odd. I could have used the su pport earlier. I've had three heart failure nurses because I've moved wards so much; I've not built up any sort of relationship with them. It might have helped if I'd had the same heart failure nurse throughout.
If I could give advice to someone with cardiomyopathy I would tell them to keep a notepad because doctors talk very fast, especially men. In terms of coping, I would suggest watching lots of television and being prepared to relinquish control to your carers as you will be stuck in bed, unable to do anything. I laugh with my mum and friends because I'm classified as disabled and get the best seats on the bus and concessions at the cinema.
I was told originally that I had six months to live but I've gone past that. In hospital my next of kin were called as the doctors didn't think I was going to make it, but I was never going to let that happen. I haven't really discussed it with my family but I suppose I should be thinking about my funeral. Night times can be especially scary as you start to ruminate about what's happened in the day.
I wonder where this year has gone and realise that I've spent it largely in hospital. It has been the most boring period of my life.
Unfortunately Liana Daley died a few weeks before publication, but we know she was pleased to have contributed. Contributors: LD wrote the main text, with help from CW; JG and KW-P wrote the text in the boxes. Competing interests: None declared. provenance and peer review: Not commissioned; not externally peer reviewed.
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A 38 year old woman who is a teacher presents with a three week history of hoarse voice after a common cold. It is intermittent, with normal voice in between. She reports a sensation of having phlegm in the throat that constantly needs to be cleared.
What you should cover
Hoarseness has a prevalence of 6% in the general population, rising to 11% for professional voice users (30% of the workforce). Most episodes are benign and resolve with vocal hygiene (see box). Laryngeal cancer is an important, but rare, cause of hoarseness (5/100 000 in males and 1/100 000 in females). Most patients with laryngeal cancer have risk factors, mainly smoking, high alcohol intake, and increasing age (72% of cancers occur over the age of 60). Heavy smoking and drinking are synergistic risk factors, and together increase risk 80-fold. • Stopping smoking and reducing alcohol consumption is of paramount importance.
History taking
• Advise vocal hygiene in every case. Consider providing this in a leaflet to aid compliance and save time during the consultation (for example, print out the box).
• Treat any possible contributing conditions; optimise treatment of asthma or rhinitis, and treat oral candidiasis related to inhaled steroids and advise on prevention.
• Trial of a proton pump inhibitor or liquid alginate may be reasonable in patients with symptoms of gastro-oesophageal reflux disease (RSI >13), but meta-analysis has not shown that proton pump inhibitors are efficacious for laryngeal symptoms presumed secondary to the disease.
• Antibiotics are ineffective for hoarseness after upper respiratory tract infection.
• Consider routine referral to ear, nose, and throat specialists for non-persistent, recurrent cases that do not meet criteria for urgent referral and fail to resolve with treatment in primary care. The team will examine the vocal cords with a nasal endoscope to identify causes such as cord polyps, nodules, granulomata, and oedema (Reinke's oedema). Many centres provide a voice clinic in conjunction with speech and language therapists.
We thank iona Heath and Daniel Toeg for their comments on the manuscript.
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examination
• Weigh the patient and compare against records.
• Examine the neck and thyroid. Red flags are lumps and lymphadenopathy.
• Examine the mouth for candidiasis.
• Respiratory and neurological examination, if indicated.
